NovaBay Pharmaceuticals, Inc. (NBY) Earnings History
Annual and quarterly earnings data from 2005 to 2024
Loading earnings history...
NBY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NBY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 66.3% | -59.7% | -73.8% |
| 2023 | 58.2% | -39.2% | -92.2% |
| 2022 | 54.0% | -100.1% | -73.6% |
| 2021 | 63.8% | -86.8% | -57.1% |
| 2020 | 60.0% | -64.7% | -111.1% |
Download Data
Export NBY earnings history in CSV or JSON format
Free sign-in required to download data
NovaBay Pharmaceuticals, Inc. (NBY) Earnings Overview
As of May 8, 2026, NovaBay Pharmaceuticals, Inc. (NBY) reported trailing twelve-month net income of $3M, reflecting +98.2% year-over-year growth. The company earned $0.55 per diluted share over the past four quarters, with a net profit margin of -73.8%.
Looking at the long-term picture, NBY's historical earnings data spans multiple years. The company achieved its highest annual net income of $3M in fiscal 2009.
NovaBay Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 66.3%, operating margin of -59.7%, and net margin of -73.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including AYTU (-$24M net income, -20.4% margin), PRPH (-$42M net income, -788.2% margin), OGEN (-$10M net income), NBY has room to improve margins relative to the peer group. Compare NBY vs AYTU →
NBY Earnings vs Peers
Earnings metrics vs comparable public companies
NBY Historical Earnings Data (2005–2024)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$7M | +25.1% | -$6M | $-2.53 | -73.8% | -59.7% |
| 2023 | -$10M | +9.1% | -$4M | $-138.65 | -92.2% | -39.2% |
| 2022 | -$11M | -82.1% | -$14M | $-353.59 | -73.6% | -100.1% |
| 2021 | -$6M | +47.2% | -$9M | $-184.09 | -57.1% | -86.8% |
| 2020 | -$11M | -14.3% | -$6M | $-385.53 | -111.1% | -64.7% |
| 2019 | -$10M | -47.6% | -$9M | $-593.63 | -146.4% | -142.4% |
| 2018 | -$7M | +11.6% | -$8M | $-564.17 | -52.3% | -62.9% |
| 2017 | -$7M | +43.7% | -$7M | $-591.81 | -40.6% | -40.1% |
| 2016 | -$13M | +30.7% | -$11M | $-1047.97 | -110.5% | -92.3% |
| 2015 | -$19M | -24.9% | -$21M | $-694.63 | -433.1% | -479.7% |
See NBY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
Is NBY growing earnings?
NBY EPS is $0.55, with earnings growth accelerating to +98.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $3M.
What are NBY's profit margins?
NovaBay Pharmaceuticals, Inc. net margin is -73.8%, with operating margin at -59.7%. Below-average margins reflect competitive or cost pressures.
How consistent are NBY's earnings?
NBY earnings data spans 2005-2024. The accelerating earnings trend is +98.2% YoY. Historical data enables comparison across business cycles.